A phase II, open label study of everolimus with fulvestrant in postmenopausal women with hormone receptor-positive HER-2 negative AI and fulvestrant treated, locally advanced or metastatic breast cancer (mBC), who progressed on or after mTor inhibitor based treatment.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2014
At a glance
- Drugs Everolimus (Primary) ; Fulvestrant
- Indications Breast cancer
- Focus Therapeutic Use
- 30 Sep 2014 New trial record